Using CD47's protection to deliver anti-cancer drugs directly to tumor cells

October 9, 2012 by Marcia Goodrich, Michigan Technological University
Ching-An Peng with students in his lab. Peng is studying new ways to get chemotherapy drugs to the site of a tumor.

(Medical Xpress)—For most of their natural lives, red blood cells hide safely under the radar of the body's immune system, thanks to a cloak of "don't eat me" protein called CD47. Ching-An Peng of Michigan Technological University wants to co-opt that clever trick to fight cancer.

Voracious called macrophages normally protect organisms by engulfing cell debris and pathogens. However, if they encounter something covered with CD47, such as a red blood cell, they tend to leave it alone. "I thought, 'Why not use CD47 to help deliver drugs?" said Peng. "We could camouflage them and avoid the immune response."

Nanoparticles hold great promise for delivering anti- directly to the site of a tumor. Getting them there, however, has been problematic, since macrophages stand at the ready to scoop the particles out of the blood stream before they can get to the the tumor and drop their cargo. Peng theorizes that if drug-bearing nanoparticles were coated with CD47, they could make it to the tumor unmolested.

CD47 also brings another weapon to the war against cancer. It binds to a special kind of protein found on tumors called an integrin. This integrin is involved with the network of that form around the tumor, blood vessels that provide the cancer with nutrients to fuel its out-of-control growth.

Thus, properly designed CD47-coated nanoparticles might deliver a one-two punch to cancer by 1) delivering and 2) choking off its food supply.

Research by Peng and his colleagues is in its early stages. They are using E. coli bacteria to mass produce CD47 in the lab using recombinant DNA technology. The next step will be to attach it to nanoparticles and expose them to macrophages, to see if the macrophages eat them up or—hopefully—ignore them.

Explore further: Research: Single antibody shrinks variety of human tumors transplanted into mice

Related Stories

Research: Single antibody shrinks variety of human tumors transplanted into mice

March 26, 2012
Human tumors transplanted into laboratory mice disappeared or shrank when scientists treated the animals with a single antibody, according to a new study from the Stanford University School of Medicine. The antibody works ...

Recommended for you

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.